Opus Genetics (IRD) Short term Debt (2021 - 2022)
Opus Genetics (IRD) posted quarterly Short term Debt of $215000.0 for Q1 2022, down 60.04% quarter-over-quarter from $538000.0 in Q4 2021.
Opus Genetics (IRD) Short term Debt (2021 - 2022) Analysis & Trends
Opus Genetics (IRD) has reported Short term Debt for 2 consecutive years, with $215000.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Short term Debt changed N/A year-over-year to $215000.0; the TTM figure through Mar 2022 stood at $215000.0 (changed N/A YoY), while the FY2021 annual figure was $538000.0, changed N/A from the prior year.
- Short term Debt fell to $215000.0 in Q1 2022 per IRD's latest filing, from $538000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $538000.0 in Q4 2021 and bottomed at $215000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 215,000.00 |
| Dec 31, 2021 | 538,000.00 |